Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625. (Q44599683)

From Wikidata

Jump to navigation Jump to search

scientific article published on 4 June 2011

Language	Label	Description	Also known as
English	Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625.	scientific article published on 4 June 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625. (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

0 references

cognitive dysfunction

1 reference

based on heuristic

inferred from title

author name string

Karen L Marquis

1

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Thomas A Comery

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Flora Jow

3

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Rachel L Navarra

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Steven M Grauer

5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Claudine Pulicicchio

6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Cody Kelley

7

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Julie A Brennan

8

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Renza Roncarati

9

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Carla Scali

10

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Simon Haydar

11

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Chiara Ghiron

12

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Georg C Terstappen

13

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

John Dunlop

14

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

4 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Psychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

218

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

635-647

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

https://scigraph.springernature.com/pub.10.1007/s00213-011-2357-6

0 references

Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2357-6

21 January 2018

Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2357-6

21 January 2018

SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2357-6

21 January 2018

The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2357-6

21 January 2018

A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2357-6

21 January 2018

Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2357-6

21 January 2018

Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2357-6

21 January 2018

Presynaptic alpha 7- and beta 2-containing nicotinic acetylcholine receptors modulate excitatory amino acid release from rat prefrontal cortex nerve terminals via distinct cellular mechanisms

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2357-6

21 January 2018

JN403, in vitro characterization of a novel nicotinic acetylcholine receptor alpha7 selective agonist.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2357-6

21 January 2018

Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2357-6

21 January 2018

Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN3462

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2357-6

21 January 2018

The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetize

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2357-6

21 January 2018

Catalepsy intensifies context-dependently irrespective of whether it is induced by intermittent or chronic dopamine deficiency

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2357-6

21 January 2018

A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2357-6

21 January 2018

Partial agonist and neuromodulatory activity of S 24795 for alpha7 nAChR responses of hippocampal interneurons.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2357-6

21 January 2018

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2357-6

21 January 2018

Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2357-6

21 January 2018

Effects of repeated testing on the incidence of haloperidol-induced catalepsy in mice

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2357-6

21 January 2018

Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2357-6

21 January 2018

Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2357-6

21 January 2018

Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2357-6

21 January 2018

Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2357-6

21 January 2018

Adjunctive galantamine, but not donepezil, enhances the antipsychotic-like effect of raclopride in rats

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2357-6

21 January 2018

Preclinical Characterization of A-582941: A Novel α7 Neuronal Nicotinic Receptor Agonist with Broad Spectrum Cognition-Enhancing Properties

1 reference

https://pubmed.ncbi.nlm.nih.gov/21643676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Smoking and schizophrenia: abnormal nicotinic receptor expression

1 reference

https://pubmed.ncbi.nlm.nih.gov/21643676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Normalization of auditory physiology by cigarette smoking in schizophrenic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21643676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacological Specificity of Conditioned Avoidance Response Inhibition in Rats: Inhibition by Neuroleptics and Correlation to Dopamine Receptor Blockade

1 reference

https://pubmed.ncbi.nlm.nih.gov/21643676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21643676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Initiatives to promote the discovery of drugs to improve cognitive function in severe mental illness

1 reference

https://pubmed.ncbi.nlm.nih.gov/21643676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00213-011-2357-6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44599683&oldid=1633008529"